We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Human T Cell and Antibody-Mediated Responses to the Mycobacterium tuberculosis Recombinant 85A, 85B, and ESAT-6 Antigens
News

Human T Cell and Antibody-Mediated Responses to the Mycobacterium tuberculosis Recombinant 85A, 85B, and ESAT-6 Antigens

Human T Cell and Antibody-Mediated Responses to the Mycobacterium tuberculosis Recombinant 85A, 85B, and ESAT-6 Antigens
News

Human T Cell and Antibody-Mediated Responses to the Mycobacterium tuberculosis Recombinant 85A, 85B, and ESAT-6 Antigens

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Human T Cell and Antibody-Mediated Responses to the Mycobacterium tuberculosis Recombinant 85A, 85B, and ESAT-6 Antigens"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Tuberculosis remains a major health problem throughout the world causing large number of deaths. Effective disease control and eradication programs require the identification of major antigens recognized by the protective responses against M. tuberculosis.

The work reported within this article demonstrates how Ag85A and ESAT-6 are antigens able to differentiate pulmonary, extra-pulmonary and tuberculosis patients undergoing chemotherapy from healthy individuals by IFN- γ production and pulmonary and under treatment patients from extra-pulmonary TB by TNF-α. Therefore, not only IFN-γ production but also TNF-α to Ag85A and ESAT-6 could be used as biomarkers for the clinical status of TB patients while IL-10 could be useful monitoring TB successful treatment.

The article is published online within the journal, Clinical and Developmental Immunology and is free to access.

Advertisement